Research Title: A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation and Multiple – Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Sponsor: Genentech, Inc.
Principal Investigator: Robert Stoltz, M.D., Ph.D.
Description: This study will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of ITV administration of FHTR2163 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Start Date: August 2017
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, COA; Halie Sklanka, CRC
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060